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Abstract. Aging in humans is a multi-factorial cellular process
that is associated with an increase in the risk of numerous
diseases including diabetes, coronary heart disease and cancer.
Aging is linked to DNA damage, and a persistent source of
DNA damage is exposure to ultraviolet (UV) radiation. As such,
identifying agents that confer protection against DNA damage
is an approach that could reduce the public health burden of
age-related disorders. Metformin and resveratrol have both
shown effectiveness in preventing several age-related diseases;
using human A549 cells, we investigated whether metformin
or resveratrol, alone or combined, prevent UVC-induced DNA
damage. We found that metformin inhibited UVC-induced
upregulation of p53, as well as downregulated the expression
of two DNA damage markers: γH2AX and p-chk2. Metformin
also upregulated DNA repair as evidenced by the increase in
expression of p53R2. Treatment with metformin also induced
cell cycle arrest in UVC-induced cells, in correlation with a
reduction in the levels of cyclin E/cdk2/Rb and cyclin B1/cdk1.
Compared to metformin, resveratrol as a single agent showed
less effectiveness in counteracting UVC-elicited cellular
responses. However, resveratrol displayed synergism when
combined with metformin as shown by the downregulation of
p53/γH2AX/p-chk2. In conclusion, the results of the present
study validate the effectiveness of metformin, alone or with
the addition of resveratrol, in reducing the risk of aging by
conferring protection against UV-induced DNA damage.
Introduction
The notion that aging and the quality of longevity of living
organisms including humans may be improved can be found
in century-old historical records (1). The topic is of interest to
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social and public health experts as well as basic and clinical
scientists. On the one hand, life expectancy of humans has
clearly benefitted from modern day medical advances that
have eradicated several diseases that at one time plagued
humankind (2,3); on the other hand, it is known that two thirds
of people die daily from age-related causes pointing to aging
as the single most significant risk factor for many human
diseases (4).
Do interventions and dietary modalities exist that can delay
the onset of aging, or counteract the deleterious effects of environmental insults impinging on the integrity of our genome,
widely considered as a major risk factor for disease‑associated
aging? It is our hypothesis that disease-associated, subclinical
aging (in relative terms) is a multistage biological process
whose duration and manifestation can be dynamically regulated by environmental and dietary, as well as genetic factors.
As a corollary, therefore, age-related diseases can be managed
in humans using agents that attenuate cellular responses to
external agents capable of damaging the integrity of the DNA
in the genome.
Accumulation of DNA damage is regarded as a cause
for aging, tumorigenesis and other inheritable diseases (5).
Exposure of cells to ultraviolet (UV) radiation results in
the generation of DNA damage and lesions, which, if left
unrepaired, can directly or indirectly lead to dysfunctional
cellular events and possibly disease-associated aging. Multiple
changes occur to counteract UV-induced DNA damage,
including the upregulation and activation of transcription
factor p53. p53 is known to play an essential role in controlling various downstream target genes, frequently as different
sets by a stimuli-specific [ionizing radiation, UV or reactive
oxygen species (ROS)] mechanism (6,7). Thus, UV-induced
p53 mediates cell cycle arrest and DNA repair and changes
the expression of ataxia telangiectasia mutated (ATM) protein
kinase and γH2AX (H2AX phosphorylated on Ser139) which
then can be used as indicators to monitor the ongoing DNA
damage induced externally by exposure to UV or by endogenously generated reactive oxygen species (ROS) (8-11).
In this study, we used human A549 cells to test and validate the ability of metformin and resveratrol, alone and in
combination, to confer protection against exposure to UVC,
known to contribute to aging by damaging genomic DNA.
Metformin, with demonstrated efficacy to restore insulin sensitivity in type II diabetes (12,13), was selected for its activity
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in managing age-related diseases including cardiovascular
disorders and cancer (14-19) by targeting the AMP-dependent
protein kinase (AMPK) (20,21), and extension of lifespan (22).
The choice of resveratrol (trans-3,4',5-trihydroxystilbene),
found abundantly in grapes (23,24), was based on its plethora
of biological activities (14-19), and documented antioxidant,
anti-inflammatory (25-28) and anti-diabetic activities (29), as
well as its ability to modulate and activate SIRT1, a key protein
for the aging process (30-33), and prolongation of life span
in mammals and other species (33-35). Results of our studies
support the effectiveness of metformin, alone or combined
with resveratrol, in reducing the risk of aging by conferring
protection against UV-induced DNA damage.
Materials and methods
Reagents. Fetal calf serum, Eagle's minimum essential
medium, penicillin and streptomycin were purchased from
Cellgro, Inc. (Herndon, VA, USA). Metformin (1,1-dimethylbiguanide chloride) and resveratrol were obtained from
Calbiochem (La Jolla, CA, USA) and LKT Laboratories
(St. Paul, MN, USA), respectively. All other chemicals and
solvents used were of analytical grade. Primary antibodies:
p53, cyclin B1, cyclin E, cdk1, cdk2, Rb, p53R2, cdc25C,
actin and secondary antibodies were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Other
antibodies for the present study were obtained from the
following sources: serine‑139-phosphorylated histone H2AX
(Upstate Biotechnology, Inc., Lake Placid, NY, USA); p21
(Cell Signaling Technology, Inc., Beverly, MA, USA); plk1
(Invitrogen Corp., Carlsbad, CA, USA), and p-chk2 (Cell
Signaling Technology, Inc.). All other chemicals and solvents
used were of analytical grade.
Cell culture. The lung carcinoma cell line A549 was purchased
from the American Type Culture Collection (ATCC; Rockville,
MD, USA). Cells were maintained in Eagle's minimum essential medium supplemented with 2 mM glutamine and Earle's
BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM
non-essential amino acids and 1 mM sodium pyruvate and
supplemented with 0.01 mg/ml bovine insulin and 10% fetal
bovine serum. Cells were seeded at a density of 5x104 cells/ml
and passaged by washing the monolayers with phosphate‑buffered saline (PBS) followed by a brief incubation with 0.25%
trypsin/EDTA.
Preparation of chemicals and treatment. Metformin and resveratrol were dissolved in dimethyl sulfoxide (DMSO) and stored
at -80˚C as 500 and 50 mM stock, respectively. Treatments
included: 0, 2.5 or 25 µM of resveratrol or 5 mM metformin
alone or in combination (5 mM metformin + 2.5 µM resveratrol
or 5 mM metformin + 25 µM resveratrol). For UV irradiation experiments, the cells were first primed with metformin
or resveratrol for 48 h and washed with PBS to remove the
chemicals. The primed cells were exposed to 20 J/m2 UVC for
10 sec, after which the UVC-exposed cells were maintained in
culture for 4 h, and harvested for further analysis.
Preparation of cell extracts and western blot analysis. To
determine the level of protein expression of various genes

examined in the present study, control and treated cells were
harvested and lysed in ice-cold RIPA buffer [50 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1%
deoxycholate, 0.1% SDS, 1 mM dithiothreitol and 10 µl/ml
protease inhibitor cocktail from Sigma Chemicals (St. Louis,
MO, USA)]. The protein concentration of the cell lysates was
determined using the Coomassie protein assay kit (Pierce,
Rockford, IL, USA) with BSA as the standard. The proteins in
cell lysates were separated by 10% SDS-PAGE and transferred
to a nitrocellulose membrane as previously described (36).
The blots were incubated overnight with various primary
antibodies, followed by incubation for 1 h with secondary antibodies. The blots were detected with an ECL detection system
(LumiGLO Peroxidase Chemiluminescent Substrate kit; KPL
Biotechnology, Inc., Gaithersburg, MD, USA), quantified by
densitometry and normalized against actin as the loading
control as previously described (37).
Cell cycle analysis. Cell cycle phase distribution was assayed
by flow cytometry as previously described (38-40); the histograms obtained were quantified for the percentage of cells in
the respective phases (G1, S and G2/M) of the cell cycle.
Results
Effects of resveratrol and metformin on DNA damage
response under normal and UVC-induced conditions. DNA
damage is an important factor contributing to carcinogenesis and the aging process. Resveratrol (18,19,23,41,42) and
metformin (14,43) have each been reported to have beneficial
effects against cancer cells, e.g., by suppressing proliferation
and induction of apoptosis (44-47), and aging, e.g., prolonging
life span in model systems (11,33,48-51). However, the effects
of these two chemicals alone or in combination on p53
expression in the context of UV-induced DNA damage have
not been investigated. Accordingly we monitored changes
in the level of total p53. A pronounced increase (~2.3-fold)
in p53 expression was observed in the UVC-induced control
cells compared to the non-exposed control cells (Fig. 1A),
suggesting that exposure to UVC resulted in the induction
of total p53. Correspondingly, no significant change in p53
expression was observed in control cells treated with either
resveratrol (2.5 and 25 µM) or metformin alone (5 mM) or in
combination (2.5 or 25 µM resveratrol combined with 5 mM
metformin) (Fig. 1A). In contrast, under the UVC exposed
condition, treatments resulted in a decrease in p53 expression
of 17-21% by resveratrol, ~60% by metformin and 59-74% by
the combined treatment (Fig. 1A). These results are consistent
with the interpretation that metformin alone or in combination with resveratrol can prevent UVC-induced p53 activation.
Next, we tested whether resveratrol and metformin may induce
DNA damage by affecting the integrity of genomic DNA
by analyzing changes in the DNA damage marker γH2AX.
In non-stressed cells, the combination of 5 mM metformin
and 25 µM resveratrol resulted in ~15% decrease in γH2AX
expression (Fig. 1B). Under the UVC-induced condition, a
slight increase in γH2AX expression was observed in cells
treated with 2.5 or 25 µM resveratrol (Fig. 1B). Surprisingly,
metformin alone or in combination with resveratrol inhibited
UVC-induced γH2AX expression (Fig. 1B). Thus, data on
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Figure 1. Effects of resveratrol and metformin on DNA damage response in A549 cells, with or without exposure to UVC. In non-UVC exposed conditions,
cells were treated with resveratrol (2.5 and 25 µM), metformin (5 mM) or in combination (2.5 or 25 µM resveratrol combined with 5 mM metformin) for 48 h.
For UVC-exposed experiments, cells were primed for 48 h as non‑UVC exposed cells, which were then followed by exposure to 20 J/m 2 UVC for 10 sec. Both
UVC exposed and non-exposed cells were maintained in culture for another 4 h and then harvested for further analysis. (A) Changes in p53 protein expression
in cells treated with different agents with or without UVC exposure were analyzed by western blot analysis. (B) The total protein expression level of γH2AX
was also determined. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as a fold difference against actin
(loading control).

prevention of DNA damage by metformin and/or resveratrol
resulting from the exposure to UVC as assayed by γH2AX
expression generally agreed with measurements of p53
changes.
Changes in cell cycle phase transition and expression of
specific signaling proteins impinging on cell cycle control by
resveratrol and metformin under UVC-induced conditions.
Alteration in p53 expression could induce an arrest in cell
cycle progression. Since minimum effects on p53 resulted from
treatment by resveratrol or metformin under non-UVC-induced
conditions, we next focused only on cells exposed to UVC. We
first determined the effects of resveratrol and metformin on
cell cycle progression by flow cytometry. Metformin alone and
in combination with a low dose of resveratrol caused a significant decrease in the S phase cell population (13.7% in control
vs. 8.8 and 7.3% in cells treated with 5 mM metformin alone
and combined with 2.5 µM resveratrol, respectively). This
decrease was accompanied by a concomitant accumulation
in the G1 phase cell population (59.1% in control vs. 69.2 and
70.9% in 5 mM metformin without and with addition of 2.5 µM
resveratrol) (Table I). To gain additional information on the

Table I. Effect of resveratrol or metformin on cell cycle distribution.
		
Treatment
G1
Control		
Resveratrol (2.5 µM)
Resveratrol (25 µM)
Metformin (5 mM)
Resveratrol (2.5 µM)
+ metformin (5 mM)
Resveratrol (25 µM)
+ metformin (5 mM)

UV (20 J/m2)
S

G2/M

59.1
60.90
53.90
69.24
70.87

13.73
14.00
13.14
8.82
7.26

22.60
21.01
21.13
13.68
14.81

65.48

11.57

15.54

underlying causes for the observed cell cycle phase transition
change, we measured levels of cell cycle regulatory proteins
cyclin E/cdk2 specifically required for G1 and S phase transition by western blot analysis. Results in Fig. 2A showed that
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Figure 2. Changes in expression of various cell cycle regulatory proteins under UVC-exposed conditions following different treatments. A549 cells were
primed with resveratrol (2.5 and 25 µM), metformin (5 mM) or in combination (2.5 or 25 µM resveratrol combined with 5 mM metformin) for 48 h and exposed
to 20 J/m 2 UVC for 10 sec. Then cells were maintained in culture for another 4 h and harvested for further analysis. (A) Western blot analysis of the changes in
cyclin E, cdk2, cyclin B1 and cdk1 protein expression. (B) The total protein expression levels of Rb, p21, plk1 and cdc25c were also determined by western blot
analysis. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as a fold difference against actin (loading control).

metformin alone or in combination with resveratrol resulted in
52-79 and 72-85% suppression of cyclin E and cdk2, respectively. Since resveratrol alone did not significantly change cell
cycle phase distribution under the conditions of exposure to
UVC, the observed increase in cyclin E expression along with
decreasing cdk2 expression following treatment by resveratrol
may reflect may reflect a compensatory regulatory adjustment
by cyclin E/cdk2 (Table I). As expected, however, a more
pronounced decrease in the expression of cyclin E as well as
cdk2 was detected in the cells treated with 5 mM metformin
alone or with the addition of 25 µM resveratrol (Fig. 2A).
Since metformin-treated cells also showed alterations in G2/M
progression, we assayed the changes in cyclin B/cdk1 expression. Following metformin treatment, downregulation of
cyclin B1 (~56%) and cdk1 (~72%) was observed, but no further
reduction on cdk1 expression occurred in cells treated with
metformin combined with 2.5 or 25 µM resveratrol (Fig. 2A).

G1 and S arrest elicited by metformin (Fig. 2B). Additionally,
we also investigated the effects of metformin and resveratrol
on the p53-p21 axis of the G1 and S checkpoint control in
response to the UVC stimuli. Resveratrol (25µM) increased
p21 expression (1.8-fold); whereas metformin alone or in
combination with resveratrol resulted in >50% downregulation
of p21 (metformin alone or with 2.5 µM resveratrol) and ~85%
decrease of p21 (metformin with 25 µM resveratrol) (Fig. 2B).
Activation of cyclin B1 and the cyclin B1/cdk1 complex is
tightly controlled by phosphorylation and de-phosphorylation via plk1 and cdc25c, respectively (52,53). Therefore,
cyclin B/cdk1-mediated G2/M progression by metformin and
resveratrol was further analyzed by the changes in plk1/cdc25c.
A more pronounced decrease in the expression of plk1/cdc25c
was detected in the cells treated with 5 mM metformin when
combined with 25 µM resveratrol (Fig. 2B); in agreement with
the cyclin B1/cdk1 changes we observed (Fig. 2A).

Cyclin E/cdk2 also plays a pivotal role in controlling Rb and
entry into the S phase. We also examined whether control of
cyclin E/cdk2 by metformin may result in a change in Rb. We
found that under the same treatment conditions a ~66% suppression of Rb was observed that could contribute to the partial

Control of DNA damage checkpoint and repair by resveratrol
and metformin under UVC-induced conditions. DNA repair
plays an important role in DNA damage responses during
anti‑carcinogenesis and anti-aging. Two tumor suppressor
proteins, checkpoint kinase 2 (Chk2) and p53R2, associated
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Figure 3. Control of DNA damage checkpoint and repair by resveratrol and
metformin under UVC-exposed conditions in A549 cells. Conditions of
priming, treatment and analysis were identical to those described in Fig. 2
legend. The total protein expression levels of p-chk2 and p53R2 were determined. The intensity of the specific immunoreactive bands was quantified
by densitometry and expressed as a fold difference against actin (loading
control).

with DNA damage checkpoint and DNA repair were further
analyzed in response to UVC. In cells treated with resveratrol,
p-chk2 and p53R2 were upregulated (Fig. 3), suggesting the
activation of DNA repair by resveratrol under UVC treatment as
a cellular protective mechanism from DNA damage. Metformin
alone or in combination with resveratrol also resulted in the
upregulation of p53R2 (Fig. 3) while downregulation of p-chk2
was found in cells treated with metformin alone or combined
with resveratrol (Fig. 3). These results suggest that in cells
exposed to UVC, metformin alone or with addition of resveratrol likely induces DNA repair via the upregulation of p53R2
without concomitantly invoking the activation of chk2.
Discussion
In previous studies, we examined multiple gero-preventive
agents by focusing on their activity in controlling the mTOR/S6
signaling pathway (54). Both metformin and resveratrol were
found to reduce constitutive DNA damage as indicated by
the inhibition of the phosphorylation of H2AX (γH2AX) and
ribosomal S6 protein expression (54). These results suggest
that metformin and resveratrol, previously regarded as prime
candidates for treating and preventing type II diabetes (12,13)
and coronary heart disease (25-28), may offer the potential to
be repositioned as candidate anti-aging drugs via the modulation of intrinsic aging factors. Indeed, the interest in resveratrol
and metformin as gero-active chemicals may have started
much earlier stemming from efforts to identify and develop
caloric restriction mimetics (CRMs) based on the longstanding
observation of McCay in the 1930s that a reduction in caloric
intake retarded aging and extended median and maximal life
span (55,56). Metformin, a biguanide currently considered the
primary stay of management for diabetes, acts as a CRM in
whole organisms by a multitude of mechanisms including at
the metabolic level, the facilitation of fatty acid oxidation and
glucose uptake in peripheral tissues as well as the suppression
of hepatic gluconeogenesis. Molecularly, metformin not only
serves as a sensor/modulator of cellular energy status, but also
as an activator and inhibitor of AMPK and mTOR, respectively, in line with the vital role it plays in growth control.
In tumorigenic settings, ample evidence has been obtained
that exposure to metformin shows efficacy in patients diag-
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nosed with malignant diseases including pancreatic (57) and
breast cancer (58), and colorectal polyps (59). Since cancer
is a disease associated with aging, it is not totally surprising
that metformin also harnesses the capacity to improve life
expectancy as befitting of a gero-protective agent. The same
considerations may apply to resveratrol (14-19); its efficacy has
been verified in all three stages of carcinogenesis (initiation,
promotion and progression) in UVB and chemically induced
skin tumor growth in mice (23,42) and in numerous animal
models of human types of cancers (18,19). To date, the roles
of resveratrol and metformin in preventing environmentally
induced external damage that contribute to aging remain
largely unknown.
In the present study, we focused on the roles resveratrol
and metformin play in modulating the cellular and molecular
changes in cancer cells elicited in response to UV challenge
using as a model UVC-stressed and unstressed A549 cells.
Specifically, DNA damage responses by resveratrol and
metformin were assessed using changes in the level of expression of p53 and γH2AX. Our results showed that metformin
at 5 mM significantly prevented the UVC-induced upregulation of p53; relatively, much less inhibition on UVC-induced
p53 expression was observed in cells treated with resveratrol (Fig. 1A). In addition, inhibition of UVC-induced
γH2AX expression was only observed in metformin and not
resveratrol treatment conditions (Fig. 1B). These findings
suggest that metformin has better preventive potential against
UVC-induced DNA damage compared to resveratrol.
Flow cytometric analysis showed differential effects on cell
cycle control by metformin and resveratrol in UVC-exposed
cells (Table I). Metformin resulted in G1 arrest and prevention
of S and G2/M entry accompanied by the inhibition in cell
cycle-associated regulatory proteins, vis-à-vis, cyclin E/cdk2,
Rb, p21 cyclin B1/cdk1 and plk1 (Fig. 2A and B). As well,
metformin downregulated p-chk2, known to be involved in a
p53-dependent cell cycle checkpoint for DNA damage (Fig. 3).
In contrast, no significant change in cell cycle transition
occurred in UVC-induced cells following resveratrol treatment (Table I), and only moderate changes to the above
mentioned G1 and S and G2/M cell cycle regulatory proteins
as well as p-chk2 were observed (Figs. 2A and B, and 3). It
is also notable that the metformin induced cell cycle arrest
at the G1 and S checkpoint under UVC conditions was not
mediated via the p53-p21 axis, but did show a correlation
with the reduction in cyclin E/cdk2 and Rb (Fig. 2). Since
metformin-mediated cell cycle control is decoupled from
p53/p21, we also tested control of p53-mediated DNA repair
by the changes in p53R2, a recently discovered DNA repair
regulatory protein (60-62). Upregulation of p53R2 expression
by metformin after UVC exposure was also observed (Fig. 3).
The effects of metformin on UVC-induced cells may therefore
be summarized as to include: i) the prevention of UVC-induced
DNA damage as supported by downregulation of p-chk2,
p53 and γH2AX (Figs. 1 and 3); ii) induction of cell cycle
arrest (Table Ι) decoupled from p53/p21; and iii) fortification of
DNA repair through p53-independent control of p53R2 (Fig. 3).
Compared to metformin, resveratrol as a single agent is
marginally effective in UVC-exposed cells, suggesting that it
operates by a different mechanism. This possibility is supported
by our results showing that, as related to the prevention of
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DNA damage in UVC-exposed A549 cells, synergism occurs
between these two agents since cells are more susceptible
to the co-treatment regimen than to each individual agent.
This conclusion is made evident by the following results:
i) suppression of DNA damage based on the downregulation
of γH2AX/p53/p-chk2 (Figs. 1 and 3); ii) inhibition of cell
cycle progression via modulation of cyclin E/cdk2, Rb,
p21 cyclin B1/cdk1 and plk1/cdc25c (Fig. 2A and B); and
iii) enhancement of DNA repair indicated by the upregulation
of p53R2 (Fig. 3).
In conclusion, our results revealed the mechanistic aspects
that underlie or contribute to the beneficial effects of metformin
and resveratrol, two readily available and widely used agents,
regarding their potential as single or combined candidates for
conferring protection against UV-induced DNA damage and
hence reducing the risk of aging.
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